ADVERTISEMENT

Piramal Pharma Q4 Results Review - Solid Quarter; Grim Near-Term Outlook: ICICI Securities

Contract development manufacturing organisation outlook intact, investment in complex hospital generics business on rise

<div class="paragraphs"><p>(Source: Piramal Pharma website)</p></div>
(Source: Piramal Pharma website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit